Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2016
Reporting Period: Specific event date of November 25, 2016.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is a regulatory milestone rather than a financial variance:
- Regulatory Acceptance: On November 25, 2016, the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for CHS-1701.
- Product: CHS-1701 is the Company's pegfilgrastim (Neulasta®) biosimilar candidate.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company issued a press release on November 29, 2016, to publicly announce the EMA acceptance. This document incorporates that press release by reference.
Guidance and Risks: This specific filing does not contain updated financial guidance, forward-looking projections, or a discussion of risks and contingencies beyond the context of the regulatory submission.
Important Facts for Investor Verification
- Verify the status of the CHS-1701 Marketing Authorization Application with the European Medicines Agency.
- Review the attached press release (Exhibit 99.1) for detailed commentary on the timeline for potential approval.
- Confirm the commercial implications of EMA acceptance for the pegfilgrastim biosimilar market.